Vita Therapeutics
Baltimore, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $31M
Overview
Creating iPSC-derived muscle cell therapies to regenerate tissue for muscular dystrophies and cardiovascular disease.
CardiovascularRegenerative MedicineRare Disease
Technology Platform
An iPSC platform engineered to consistently produce specific, therapeutic-grade muscle cell types (skeletal and cardiac) for allogeneic cell transplantation.
Funding History
1Total raised:$31M
Venture$31M
Opportunities
Degenerative muscle diseases represent areas of severe unmet need with no cures, creating a clear pathway for a successful regenerative therapy.
Risk Factors
High biological complexity in achieving functional integration and persistence of transplanted cells in diseased muscle tissue.
Competitive Landscape
Competes with gene therapy and other cell therapy companies targeting muscular dystrophies and heart failure, a crowded but high-potential therapeutic area.